Hematopoietic Stem Cell Transplantation
📧 Sign up to get email alerts when something new happens for Hematopoietic Stem Cell Transplantation.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2023-08-04EMA Withdrawn: Busilvex (busulfan) — Pierre Fabre Medicament
EMA withdrew Busilvex (busulfan) from the market; the product is no longer authorized in the EU.
-
EMA withdrawal · 2020-02-17EMA Application withdrawn: Luxceptar — Kiadis Pharma Netherlands B.V.
EMA status shows that the Luxceptar application has been withdrawn by the applicant.
-
EMA withdrawal · 2017-01-19EMA Withdrawn: Biograstim (filgrastim) — AbZ-Pharma GmbH
Biograstim (filgrastim) by AbZ-Pharma GmbH has been withdrawn from the market.
-
EMA withdrawal · 2016-07-22EMA Application withdrawn: Begedina (begelomab) — Adienne S.r.l. S.U.
EMA withdrew the application for Begedina (begelomab) by Adienne S.r.l. S.U. for graft-versus-host disease/Hematopoietic Stem Cell Transplan…
-
EMA withdrawal · 2011-07-20EMA Withdrawn: Filgrastim ratiopharm (filgrastim) — Ratiopharm GmbH
Withdrawn European medicines agency status for filgrastim ratiopharm by Ratiopharm GmbH.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.